NewLink raises funds to advance HyperAcute cancer vaccines
This article was originally published in Scrip
Executive Summary
NewLink Genetics has raised $7.5 million in a series D financing to advance the clinical development of its therapeutic cancer products. The round involved additional funding from prior investors.